{"version":"1.0","provider_name":"Site da Brakke Consulting","provider_url":"https:\/\/brakkeconsulting.com\/pt","title":"News from Brakke Consulting","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"ui1a5R5e8Z\"><a href=\"https:\/\/brakkeconsulting.com\/pt\/30216-2\/\">Brakke Viewpoint 4 de mar\u00e7o de 2022<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/brakkeconsulting.com\/pt\/30216-2\/embed\/#?secret=ui1a5R5e8Z\" width=\"600\" height=\"338\" title=\"&#8220;Brakke Viewpoint March 4, 2022&#8221; &#8212; Brakke Consulting Website\" data-secret=\"ui1a5R5e8Z\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/brakkeconsulting.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>","description":"Zoetis\u2019s Draxxin\u00ae has been the best example for me to use to explain that livestock producers will pay for innovation.\u00a0 Tulathromycin, the antibiotic in Draxxin, is highly effective and livestock producers are willing to pay the high price for it to treat their cattle and swine \u2013 it works. Merck and Elanco now join Bimeda, Ceva and Virbac in having a generic tulathromycin approved, bringing the total FDA approved generic products to five, proof that imitation is the greatest form of flattery in animal health as well. In Zoetis\u2019s earnings call last month, they announced that generic competition reduced Draxxin revenue 15% in 2021 compared to 2020 and they expect another decline in 2022 of 20% compared to 2021 \u2013 peak sales are now in the past. Unfortunately, these tulathromycin competitors will be battling in a livestock market this year that is forecasted to not grow much from 2021.\u00a0 The USDA expects beef production to be up fractionally in 2022 and pork production for 2022 will likely be slightly lower that 2021.\u00a0 And producer profits will be under pressure all year due to higher feed and input costs.\u00a0 (But tulathromycin costs won\u2019t be higher.) Draxxin is a great product, a great brand.\u00a0 Given the successful innovation from Zoetis and the other major animal health companies, we hope there is aView Full Post;"}